Issue of Equity and Total Voting Rights | 22-Jan-2024 | 10:51 | RNS |
Appointment of Christina Coughlin | 19-Jan-2024 | 07:00 | RNS |
Appointment of Chief Business Officer | 19-Dec-2023 | 07:00 | RNS |
ALS-6000-101 Phase 1a Study Data | 13-Dec-2023 | 07:00 | RNS |
Shareholder update to review AVA6000 Phase 1a data | 04-Dec-2023 | 07:00 | RNS |
Block Listing Six Monthly Return | 27-Oct-2023 | 07:00 | RNS |
Issue of Equity and Total Voting Rights | 23-Oct-2023 | 13:30 | RNS |
Block Listing Application to AIM | 18-Oct-2023 | 13:00 | RNS |
Avacta to present at AACR-NCI-EORTC conference | 05-Oct-2023 | 07:00 | RNS |
Interim Results for the Period Ending 30 June 2023 | 28-Sep-2023 | 07:00 | RNS |
Issue of Equity and Total Voting Rights | 20-Sep-2023 | 14:00 | RNS |
Peel Hunt Appointed as Joint Broker | 20-Sep-2023 | 07:01 | RNS |
Appointment Dr.Christina Coughlin as a consultant | 20-Sep-2023 | 07:00 | RNS |
Successful Completion of Sixth Dose Escalation | 19-Sep-2023 | 07:00 | RNS |
Notice of Results | 06-Sep-2023 | 07:00 | RNS |
Currency | UK Pounds |
Share Price | 48.30p |
Change Today | -0.50p |
% Change | -1.02 % |
52 Week High | 159.60 |
52 Week Low | 44.50 |
Volume | 3,024,260 |
Shares Issued | 359.04m |
Market Cap | £173.42m |
RiskGrade | 461 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 0 |
Buy | 2 |
Neutral | 0 |
Sell | 1 |
Strong Sell | 0 |
Total | 3 |
No dividends found |
Time | Volume / Share Price |
17:08 | 9,500 @ 48.30p |
16:41 | 184,531 @ 49.41p |
16:35 | 39,618 @ 48.30p |
16:35 | 18,987 @ 48.30p |
16:35 | 17,879 @ 48.30p |
CEO | Alastair Smith |
CFO | Tony Peter Gardiner |
You are here: research